Lung cancer patients with intergenic ALK fusions respond to ALK-TKIs.[6–8]ALK fusion is a risk factor for brain patients with advanced NSCLC.[9] Clinical trials of TKI in NSCLC patients with BM have shown a high percentage of objective responses, prolonged PFS, and improved quality of life. This evidence concerns the gene ALK and non-small cell lung carcinoma.